Cyclerion Therapeutics (CYCN) Stock: Buy, Sell, or Hold?
CYCN - Cyclerion Therapeutics, Inc. Common Stock
$3.36
-0.89 (-20.94%)
âŧ
5d:
-8.7%
30d:
-5.88%
90d:
+11.63%
WAIT
LOW Confidence
Analysis Updated: Sep 8, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When CYCN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CYCN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CYCN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CYCN is currently trading at $3.36, which is considered fair based on recent price action.
Technical Outlook: Technically, CYCN is showing support break momentum. Immediate support is located at $2.82, while resistance sits at $5.19. Short-term momentum is weak, with the stock down 20.9% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.00 (+138.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CYCN is showing support break momentum. Immediate support is located at $2.82, while resistance sits at $5.19. Short-term momentum is weak, with the stock down 20.9% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.00 (+138.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
46/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
64.2%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BEARISH: Downward momentum (-20.9%)
- BULLISH: Trading 138.1% below Wall St target ($8.00)
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Support & Resistance Levels
Support Level
$2.82
Resistance Level
$5.19
Current Trend
Support Break
Technical data as of
Sep 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.39
Wall Street Target
$8.00
(+138.1%)
Revenue Growth (YoY)
-43.2%
Share & Embed Analysis
Last updated: October 24, 2026 12:07 AM ET
Data refreshes hourly during market hours. Next update: 1:07 AM
Data refreshes hourly during market hours. Next update: 1:07 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CYCN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 38 SELL |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal PharmaceuticalsâĻ |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
PVLA
Palvella Therapeutics, IâĻ |
STRONG BUY
15 analysts |
$231 | 60 HOLD |
